Investment Landscape: Vascular Dementia covers the current R&D investment,
clinical trial pipeline, and funding trends for Vascular Dementia research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 0
Active Trials (Recruiting/Active): 0
Vascular dementia has 0 total clinical trials, representing the second most common cause of dementia after Alzheimer's. The vascular nature of the disease offers unique therapeutic opportunities targeting cerebrovascular health and cognitive reserve.
VaD research is benefiting from advances in neuroimaging for vascular damage assessment. The connection between cardiovascular health and cognitive decline is driving investment in preventive approaches. Small vessel disease targeting and blood-brain barrier protection represent emerging therapeutic frontiers.
Only 0.0% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01